Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain.
Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain.
J Am Coll Cardiol. 2014 Jan 21;63(2):158-66. doi: 10.1016/j.jacc.2013.07.087. Epub 2013 Sep 24.
ST2 and galectin-3 (Gal-3) were compared head-to-head for long-term risk stratification in an ambulatory heart failure (HF) population on top of other risk factors including N-terminal pro-B-type natriuretic peptide.
ST2 and Gal-3 are promising biomarkers of myocardial fibrosis and remodeling in HF.
This cohort study included 876 patients (median age: 70 years, median left ventricular ejection fraction: 34%). The 2 biomarkers were evaluated relative to conventional assessment (11 risk factors) plus N-terminal pro-B-type natriuretic peptide in terms of discrimination, calibration, and reclassification analysis. Endpoints were 5-year all-cause and cardiovascular mortality, and the combined all-cause death/HF hospitalization.
During a median follow-up of 4.2 years (5.9 for alive patients), 392 patients died. In bivariate analysis, Gal-3 and ST2 were independent variables for all endpoints. In multivariate analysis, only ST2 remained independently associated with cardiovascular mortality (hazard ratio: 1.27, 95% confidence interval [CI]: 1.05 to 1.53, p = 0.014). Incorporation of ST2 into a full-adjusted model for all-cause mortality (including clinical variables and N-terminal pro-B-type natriuretic peptide) improved discrimination (C-statistic: 0.77, p = 0.004) and calibration, and reclassified significantly better (integrated discrimination improvement: 1.5, 95% CI: 0.5 to 2.5, p = 0.003; net reclassification index: 9.4, 95% CI: 4.8 to 14.1, p < 0.001). Incorporation of Gal-3 showed no significant increase in discrimination or reclassification and worse calibration metrics. On direct model comparison, ST2 was superior to Gal-3.
Head-to-head comparison of fibrosis biomarkers ST2 and Gal-3 in chronic HF revealed superiority of ST2 over Gal-3 in risk stratification. The incremental predictive contribution of Gal-3 to existing clinical risk factors was trivial.
在一个包含其他风险因素(包括 N 末端 B 型利钠肽前体)的门诊心力衰竭(HF)患者人群中,将 ST2 和半乳糖凝集素-3(Gal-3)进行头对头比较,以进行长期风险分层。
ST2 和 Gal-3 是心力衰竭中心肌纤维化和重塑的有前途的生物标志物。
这项队列研究纳入了 876 例患者(中位年龄:70 岁,中位左心室射血分数:34%)。在考虑到常规评估(11 个危险因素)和 N 末端 B 型利钠肽前体的情况下,评估这 2 个生物标志物在区分度、校准度和再分类分析方面的表现。终点为 5 年全因和心血管死亡率,以及全因死亡/心力衰竭住院的联合终点。
在中位随访 4.2 年(存活患者的中位随访时间为 5.9 年)期间,有 392 例患者死亡。在单变量分析中,Gal-3 和 ST2 是所有终点的独立变量。在多变量分析中,只有 ST2 与心血管死亡率独立相关(风险比:1.27,95%置信区间[CI]:1.05 至 1.53,p=0.014)。将 ST2 纳入全因死亡率的全调整模型(包括临床变量和 N 末端 B 型利钠肽前体)可提高区分度(C 统计量:0.77,p=0.004)和校准度,并能显著更好地重新分类(综合区分改善:1.5,95%CI:0.5 至 2.5,p=0.003;净重新分类指数:9.4,95%CI:4.8 至 14.1,p<0.001)。纳入 Gal-3 并未显著提高区分度或重新分类,反而降低了校准度指标。直接模型比较显示,ST2 优于 Gal-3。
在慢性 HF 中,纤维化生物标志物 ST2 和 Gal-3 的头对头比较显示,ST2 在风险分层方面优于 Gal-3。Gal-3 对现有临床危险因素的预测贡献增量微不足道。